OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

【24h】

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

机译：奥林匹克延长了整体生存和安全的延长的后续行动：奥拉帕里布对医师的选择治疗患者的种系BRCA突变和Her2阴性转移性乳腺癌

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共5页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：奥林匹克延长了整体生存和安全的延长的后续行动：奥拉帕里布对医师的选择治疗患者的种系BRCA突变和Her2阴性转移性乳腺癌
2. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial [J] . Robson Mark, Ruddy Kathryn J., Im Seock-Ah, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：患有种系BRCA突变和HER2阴性转移性乳腺癌患者的患者报告的结果在奥林匹克审判试验中接受奥帕里布与化疗
3. Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial [J] . Ettl J., Quek R. G. W., Lee K. -H., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第9期

机译：塔罗帕里布的生活质量与医生在患者中选择化疗选择伴有先进的乳腺癌和种系BRCA1 / 2突变：患者报告的来自Helcaca的结果III III试验
4. Identification of potential long non-coding RNA biomarkers for breast cancer patients with somatic BRCA1 mutations from RNA-Seq datasets [C] . Jia-Hua Cai, Yu-Ching Chen, Hsueh-Ting Chu, IEEE International Conference on Bioinformatics and Bioengineering . 2018

机译：鉴定来自RNA-SEQ数据集的乳腺癌患者乳腺癌患者的潜在长期非编码RNA生物标志物
5. Breast cancer risk after chemoprevention in BRCA1 versus BRCA2 mutation carriers. [D] . Shaver, Jamie. 2011

机译：BRCA1和BRCA2突变携带者进行化学预防后的乳腺癌风险。
6. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer [O] . M E Robson, N Tung, P Conte, -1

机译：OlympiAD最终总生存期和耐受性结果：奥拉帕比与化学疗法治疗具有种系BRCA突变和HER2阴性转移性乳腺癌的医生的选择
7. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer [O] . M.E. Robson, N. Tung, P. Conte, 2019

机译：奥林匹克终整体生存和耐受性结果：奥拉帕里布与医师的化疗治疗医师在患有种系BRCA突变和Her2阴性转移性乳腺癌患者中的选择

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

著录项

相似文献

相关主题

期刊订阅